Genexine, Inc. is a publicly traded, clinical-stage biotechnology company focused on developing and commercializing immunotherapeutics and next-generation . Its primary technology platforms are Therapeutic DNA vaccine and hyFc® long-acting technology and bioPROTAC. The company has multiple products in clinical development including several undergoing Phase 3 registrational trials. The company's proprietary pipeline includes GX-188E (tirvalimogene teraplasmid) for head and neck cancer and cervical cancer, GX-I7 (efineptakin alfa) for multiple solid cancers and ARS, GX-H9 (eftansomatropin alfa) for Pediatric Growth Hormone Deficiency and GX-E4 for CKD-induced anemia, among others. in 2024, Genexine has completed a merger with 'EPD biotherapeutics' and acquired future focusing new modality 'bioPROTAC' platform technology which now in pre-clinical development focusing on oncology. The company has established multiple partnerships with global companies in order to expedite product development and commercialization and create significant value. Genexine is listed on the Korean exchange (KOSDAQ: 095700) and is headquartered in Seoul, Korea. Genexine is committed to the well-being and care of patients worldwide. For more information about Genexine, please visit at www.genexine.com.
我们正在追踪 Genexine, Inc. 的市场扩张
Genexine, Inc. 的国际扩张与竞争对手的对比情况
Genexine, Inc.你条形图显示所对比公司之间的相对规模。
列5| 公司 | 市场 | 新市场 | 势头 | 活动 | 扩张评分 |
|---|---|---|---|---|---|
 Genexine, Inc.你 | 0 | 0 | — | 0 | 0 |
当前没有招聘
注册以跟踪该公司，并在发生变化时第一时间获得提醒。
没有进行中的营销活动
注册以跟踪该公司，并在发生变化时第一时间获得提醒。
韩国政府增加生物技术研发预算，专注于人工智能驱动的抗体开发和生物仿制药项目。预计普罗蒂纳和基因信等公司将受益。
Oscotech举行在线简报会，解释子公司Genexine上市的必要性和未来股东回报计划，强调这不是分拆上市，而是研发资金的必要策略。
解锁已验证邮箱与直拨电话
免费 · 无需信用卡
关于 Genexine, Inc. 的业务、市场和增长信号的快速解答。
